Last reviewed · How we verify
Nepafenac 0.1% eyedrops
Nepafenac 0.1% eyedrops, marketed by Università degli Studi di Brescia, is a postoperative ocular inflammation and pain management solution. The key composition patent expires in 2028, providing a period of exclusivity and potential market protection. The primary risk is the lack of revenue data, which may indicate limited commercial success or market penetration.
At a glance
| Generic name | Nepafenac 0.1% eyedrops |
|---|---|
| Sponsor | Università degli Studi di Brescia |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery (NA)
- Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy (PHASE4)
- CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops (PHASE2)
- Macular Edema Nepafenac vs. Difluprednate Uveitis Trial (PHASE4)
- Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1% (PHASE4)
- Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification (PHASE2)
- PGE2 Levels in Patient Treated With NSAIDs (PHASE3)
- Efficacy and Necessity of Anti-inflammatory Drops After Laser Peripheral Iridotomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nepafenac 0.1% eyedrops CI brief — competitive landscape report
- Nepafenac 0.1% eyedrops updates RSS · CI watch RSS
- Università degli Studi di Brescia portfolio CI